NCT01401673

Phase II Open-Label Pilot Study of V3381 in Chronic Cough

Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients Attending a Specialist Clinic

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Vernalis (R&D) Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. Central sensitisation is a hyper-excitability of the sensory nerves as they join the central nervous system, and is believed to be mediated by the N-Methyl-D-Aspartate (NMDA) receptor\[1-3\].

Conditions

• Cough

Interventions

Type	Name	Description
DRUG	Indantadol	Titration

Timeline

• Start date: 2009-10-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2011-07-25
• Last updated: 2011-07-25

Locations

1 site across 1 country: United Kingdom